Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study

被引:535
|
作者
Garnero, P
Sornay-Rendu, E
Claustrat, B
Delmas, PD
机构
[1] Hop Edouard Herriot, INSERM, Res Unit 403, F-69437 Lyon 03, France
[2] Hop Neurocardiol, Ctr Med Nucl, Lyon, France
关键词
osteoporosis; bone markers; estrogens; androgens; parathyroid hormone;
D O I
10.1359/jbmr.2000.15.8.1526
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mechanisms leading to increased bone loss and skeletal fragility in women with postmenopausal osteoporosis are still poorly understood. Increased bone resorption, low serum estradiol and high serum sex-hormone-binding globulin (SHBG) recently have been reported as predictors of vertebral and hip fractures in elderly women. In a cohort of healthy untreated younger postmenopausal women aged 50-89 years (mean, 64 years), we compared baseline levels of bone markers and endogenous hormones in 55 women who subsequently had a fracture (20 vertebral and 35 peripheral fractures) with levels in the 380 women who did not fracture during a mean 5 years of follow-up. Women with levels in the highest quartile of four bone resorption markers including urinary-free deoxypyridinoline (D-Pyr), urinary type I collagen N-telopeptides (NTX), and urinary and serum type I collagen C-telopeptides (CTX) had about a a-fold increased risk of fractures compared with women with levels in the three lowest quartiles with relative risk (RR) and 95% CI of 1.8 (1.0-3.4) for free D-Pyr, 1.7 (0.9-3.2) for urinary NTX, 2.3 (1.3-4.1) for urinary CTX, and 2.1 (1.2-3.8) for serum CTX. Serum levels of bone alkaline phosphatase (BAP) in the highest quartile were associated with an RR of fracture of 2.4 (1.3-4.2). Women with serum levels of estradiol and dehydroepiandrosterone (DHEA) sulfate in the lowest quartile had an RR of fracture of 2.2 (1.2-4.0) and 2.1 (1.2-3.8), respectively. Increased levels of SHBG and intact parathyroid hormone (PTH) were moderately associated with an increased risk of fracture. Similar results were obtained when the analysis was restricted to symptomatic vertebral and nonvertebral fractures. Adjustment of biochemical markers by hormone levels did not significantly alter the results. Women with both high bone resorption markers and low estradiol (or low DHEA sulfate) had a higher risk of fracture with RRs of 3.0-3.3 (p < 0.001). After adjustment for bone mineral density (BMD) of the hip, spine, radius, or total body, bone markers and hormones were still predictive of fracture risk with similar RRs. We conclude that high levels of some biochemical markers of bone turnover, low serum estradiol, low DHEA sulfate, high SHBG, and high PTH are associated with increased risk of osteoporotic fracture in postmenopausal women, independently of each other and of BMD. The mechanism by which some postmenopausal women have an increased rate of bone turnover leading to an increased risk of fracture remains to be elucidated.
引用
收藏
页码:1526 / 1536
页数:11
相关论文
共 50 条
  • [1] Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study
    Garnero, P.
    Sornay-Rendu, E.
    Munoz, F.
    Borel, O.
    Chapurlat, R. D.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (02) : 489 - 494
  • [2] Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study
    P. Garnero
    E. Sornay-Rendu
    F. Munoz
    O. Borel
    R. D. Chapurlat
    Osteoporosis International, 2013, 24 : 489 - 494
  • [3] Study of some common biochemical bone turnover markers in postmenopausal women
    Sachdeva A.
    Seth S.
    Khosla A.H.
    Sachdeva S.
    Indian Journal of Clinical Biochemistry, 2005, 20 (1) : 131 - 134
  • [4] Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: The OFELY study
    Garnero, P
    Mulleman, D
    Munoz, F
    Sornay-Rendu, E
    Delmas, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (10) : 1789 - 1794
  • [5] Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
    Komi, Janne
    Lankinen, Kari S.
    DeGregorio, Michael
    Heikkinen, Jorma
    Saarikoski, Seppo
    Tuppurainen, Marjo
    Halonen, Kaija
    Lammintausta, Risto
    Vaananen, Kalervo
    Ylikorkala, Olavi
    Erkkola, Risto
    JOURNAL OF BONE AND MINERAL METABOLISM, 2006, 24 (04) : 314 - 318
  • [6] Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
    Janne Komi
    Kari S. Lankinen
    Michael DeGregorio
    Jorma Heikkinen
    Seppo Saarikoski
    Marjo Tuppurainen
    Kaija Halonen
    Risto Lammintausta
    Kalervo Väänänen
    Olavi Ylikorkala
    Risto Erkkola
    Journal of Bone and Mineral Metabolism, 2006, 24 : 314 - 318
  • [7] Bone turnover markers in Spanish postmenopausal women The Camargo cohort study
    Martinez, Josefina
    Olmos, Jose M.
    Hernandez, Jose L.
    Pinedo, Gabriel
    Llorca, Javier
    Obregon, Eduardo
    Valero, Carmen
    Gonzalez-Macias, Jesus
    CLINICA CHIMICA ACTA, 2009, 409 (1-2) : 70 - 74
  • [8] Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women
    De Leo, V
    Ditto, A
    la Marca, A
    Lanzetta, D
    Massafra, C
    Morgante, G
    CALCIFIED TISSUE INTERNATIONAL, 2000, 66 (04) : 263 - 267
  • [9] Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis
    Camacho, Pauline M.
    Lopez, Norma A.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2008, 46 (10) : 1345 - 1357
  • [10] Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism
    Adolf, Christian
    Braun, Leah T.
    Fuss, Carmina T.
    Hahner, Stefanie
    Kuenzel, Heike
    Handgriff, Laura
    Sturm, Lisa
    Heinrich, Daniel A.
    Schneider, Holger
    Bidlingmaier, Martin
    Reincke, Martin
    ENDOCRINE, 2020, 69 (03) : 625 - 633